论文部分内容阅读
目的:探讨、分析罗格列酮对血管、血压、血脂、心脏及一些常见心血管疾病危险因素的影响。方法:以近年来部分国、内外有关罗格列酮的研究文献为参考资料。结果:罗格列酮具有潜在的心血管保护作用,可使血压下降,能不同程度地降低三酰甘油水平,能使心肌梗死面积减小。罗格列酮通过降低胰岛素抵抗,提高胰岛素敏感性使一些心血管疾病危险因素均有不同程度改善。结论:罗格列酮是目前治疗2型糖尿病较好的胰岛素增敏剂,其对心血管疾病的影响还不能定论,期待长期的、有针对性的临床研究证实。
Objective: To investigate and analyze the effects of rosiglitazone on the risk factors of blood vessels, blood pressure, blood lipids, heart and some common cardiovascular diseases. Methods: In recent years, some countries, both inside and outside of rosiglitazone research literature as a reference. Results: Rosiglitazone has a potential cardiovascular protective effect, can reduce blood pressure, can reduce the level of triglyceride to varying degrees, myocardial infarction area can be reduced. Rosiglitazone improved some of the cardiovascular disease risk factors by reducing insulin resistance and increasing insulin sensitivity. CONCLUSION: Rosiglitazone is a good insulin sensitizer for the treatment of type 2 diabetes. The effect of rosiglitazone on cardiovascular disease is still inconclusive. It is expected that long-term and targeted clinical studies will confirm this.